Osteoprotegerin as a Predictor of Coronary Artery Disease and Cardiovascular Mortality and Morbidity

Journal of the American College of Cardiology

Volumn 55, Issue 19, 2010, Pages 2049-2061

  Venuraju, Shreenidhi M ^a   Yerramasu, Ajay ^a   Corder, Roger ^b   Lahiri, Avijit ^a,c,d  

^a WELLINGTON HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c MIDDLESEX UNIVERSITY   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

atherosclerosis; osteoprotegerin; receptor activator of nuclear factor B ligand; tumor necrosis factor related apoptosis inducing ligand; vascular calcification

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ATHEROGENESIS; ATHEROSCLEROSIS; BIOCHEMISTRY; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; DISEASE MODEL; HEART LEFT VENTRICLE FAILURE; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; VASCULAR BIOLOGY;

ANIMALS; CORONARY ARTERY DISEASE; HUMANS; OSTEOPROTEGERIN; PREDICTIVE VALUE OF TESTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77951645187     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.03.013     Document Type: Review

References (117)

1. Bagger Y.Z., Rasmussen H.B., Alexandersen P., et al. Links between cardiovascular disease and osteoporosis in post-menopausal women: serum lipids or atherosclerosis per se?. Osteoporos Int 18 (2007) 505-512
2. Bagger Y.Z., Tankó L.B., Alexandersen P., Qin G., and Christiansen C. Prospective Epidemiological Risk Factors Study Group. Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J Intern Med 259 (2006) 598-605
3. Schulz E., Arfai K., Liu X., Sayre J., and Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 89 (2004) 4246-4253
4. Berra E., Benziri E., Ginouves A., et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-α in normoxia. EMBO J 22 (2003) 4082-4090
5. Min J.H., Yang H., Ivan M., et al. Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science 296 (2002) 1886-1889
6. Olsson A.K., Dimberg A., Kreuger J., and Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 7 (2006) 359-371
7. Huber T.L., Kouskoff V., Fehling H.J., Palis J., and Keller G. Haemangioblast commitment is initiated in the primitive streak of the mouse embryo. Nature 432 (2004) 625-630
8. Choi K., Kennedy M., Kazarov A., Papadimitrou J.C., and Keller G. A common precursor for hematopoietic and endothelial cells. Development 125 (1998) 725-732
9. Calvi L.M., Adams G.B., Weibrecht K.W., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425 (2003) 841-846
10. Golledge J., McCann M., Mangan S., Lam A., and Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 35 (2004) 1636-1641
11. Giachelli C.M., Bae N., Almeida M., et al. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 92 (1993) 1686-1696
12. Boström K., Watson K.E., Horn S., Wortham C., Herman I.M., and Demer L.L. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 91 (1993) 1800-1809
13. Ikeda T., Shirasawa T., Esaki Y., et al. Osteopontin mRNA is expressed by smooth-muscle derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 92 (1993) 2814-2820
14. Ohmori R., Momiyama Y., Taniguchi H., et al. Plasma osteopontin levels are associated with severity and extent of coronary artery disease. Atherosclerosis 170 (2003) 333-337
15. Yamaguchi K., Kinosaki M., Goto M., et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 273 (1998) 5117-5123
16. Morinaga T., Nakagawa N., Yasuda H., Tsuda E., and Higashio K. Cloning and characterization of the gene encoding osteoprotegerin/osteoclastogenesis inhibitory factor. Eur J Biochem 254 (1998) 685-691
17. Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 (1998) 1260-1268
18. Kong Y.Y., Yoshida H., Sarosi I., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999) 315-323
19. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
20. Hofbauer L.C., and Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292 (2004) 490-495
21. Gilmore T.D. Introduction to NFκB: players, pathways and perspectives. Oncogene 25 (2006) 6680-6684
22. Zannettino C.A., Holding A.C., Diamond P., et al. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 204 (2005) 714-723
23. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANK-L and osteoprotegerin. Circ Res 95 (2004) 1046-1057
24. Wiley S.R., Schooley K., Smolak P.J., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
25. Pan G., Ni J., Wei Y.F., et al. An antagonist decoy receptor and death-domain containing receptor for TRAIL. Science 277 (1997) 815-818
26. Schneider P., Thome M., Burns K., et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 7 (1997) 831-836
27. Griffith T.S., Chin W.A., Jackson G.C., Lynch D.S., and Kubin M.Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161 (1998) 2833-2840
28. Secchiero P., Gonelli A., Carnevale E., et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107 (2003) 2250-2256
29. Price P.A., June H.H., Buckley J.R., and Williamson M.K. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 21 (2001) 1610-1616
30. Bennett B.J., Scatena M., Kirk E.A., et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 26 (2006) 2117-2124
31. Min H., Morony S., Sarosi I., et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192 (2000) 463-474
32. Morony S., Tintut Y., Zhang Z., et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 117 (2008) 411-420
33. Kaden J.J., Bickelhaupt S., Grobholz R., et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 36 (2004) 57-66
34. Proudfoot D., Skepper J.N., Shanahan C.M., and Weissberg P.L. Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression. Arterioscler Thromb Vasc Biol 18 (1998) 379-388
35. Canfield A.E., Sutton A.B., Hoyland J.A., and Schor A.M. Association of thrombospondin-1 with osteogenic differentiation of retinal pericytes in-vitro. J Cell Sci 109 (1996) 343-353
36. Dhore C.R., Cleutjens J.P., Lutgens E., Cleutjens K.B., and Geusens P.P. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 21 (2001) 1998-2003
37. Panizo S., Cardus A., Encinas M., et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 104 (2009) 1041-1048
38. Tintut Y., Patel J., Parhami F., and Demer L.L. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 102 (2000) 2636-2642
39. Okazaki H., Shioi A., Hirowatari K., et al. Phosphatidylinositol 3-kinase/akt pathway regulates inflammatory mediators-induced calcification of human vascular smooth muscle cells. Osaka City Med J 55 (2009) 71-80
40. Major A.S., Fazio S., and Linton M.F. B-Lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 22 (2002) 1892-1898
41. Yun T.J., Tallquist M.D., Aicher A., et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B-cell development and function. J Immunol 166 (2001) 1482-1491
42. Schoppet M., Sattler A.M., Schaefer J.R., et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88 (2003) 1024-1028
43. Gannagé-Yared M.H., Fares F., Semaan M., Khalife S., and Jambart S. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf) 64 (2006) 652-658
44. Anand D.V., Lahiri A., Lim E., Hopkins D., and Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type-2 diabetic subjects. J Am Coll Cardiol 47 (2006) 1850-1857
45. Khosla S., Arrighi H.M., Melton III L.J., et al. Correlates of osteoprotegerin levels in women and men. Osteoporos Int 13 (2002) 394-399
46. Rogers A., Saleh G., Hannon R.A., Greenfield D., and Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 87 (2002) 4470-4475
47. Szulc P., Hofbauer L.C., Heufelder A.E., Roth S., and Delmas P.D. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 86 (2001) 3162-3165
48. Clancy P., Oliver L., Jayalath R., Buttner P., and Golledge J. Assessment of a serum assay for quantification of abdominal aortic calcification. Arterioscler Thromb Vasc Biol 26 (2006) 2574-2576
49. Moran C.S., McCann M., Karan M., et al. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 111 (2005) 3119-3125
50. Moran C.S., Cullen B., Campbell J.H., and Golledge J. Interaction between angiotensin II, osteoprotegerin and peroxisome proliferator-activated receptor-gamma in abdominal aortic aneurysm. J Vasc Res 46 (2009) 209-217
51. Ziegler S., Kudlacek S., Luger A., and Mina E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 182 (2005) 175-180
52. Pennisi P., Signorelli S.S., Riccobene S., Celotta G., and Di Pino L. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int 15 (2004) 389-395
53. Mangan S.H., Campenhout A.V., Rush C., and Golledege J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumour necrosis factor-α associated with induction of angiopoietin-2. Cardiovasc Res 76 (2007) 494-505
54. Blankenberg S., Barbaux S., and Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 170 (2003) 191-203
55. Secchiero P., Corallini F., Pandolfi A., et al. An increased serum osteoprotegerin release characterizes the early onset of diabetes mellitus and may contribute to endothelial dysfunction. Am J Pathol 169 (2006) 2236-2244
56. Sandberg W.J., Yndestad A., Øie E., et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 26 (2006) 857-863
57. Mosheimer B.A., Kaneider N.C., Feistritzer C., Sturn D.H., and Wiedermann C.J. Expression and function of RANK in human monocyte chemotaxis. Arthritis Rheum 50 (2004) 2309-2316
58. Aderka D., Engelmann H., Maor Y., Brakebusch C., and Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175 (1992) 323-329
59. Newby A.C. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 28 (2008) 21080-14
60. Molloy K.J., Thompson M.M., Jones J.L., et al. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation 110 (2004) 337-343
61. Montecucco F., Steffens S., and Mach F. The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability?. Clin Dev Immunol 2007 (2007) 75805
62. Ren M.Y., Sui S.J., Zhang Y., et al. Increased plasma osteoprotegerin levels are associated with the presence and severity of acute coronary syndrome. Acta Cardiol 63 (2008) 615-622
63. Jono S., Ikari Y., Shioi A., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106 (2002) 1192-1194
64. Semb A.G., Ueland T., Aukrust P., et al. Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol 29 (2009) 975-980
65. Kiechl S., Schett G., Schwaiger J., et al. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation 116 (2007) 385-391
66. Crisfaulli A., Micari A., Altavilla D., et al. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond) 109 (2005) 389-395
67. Schoppet M., Schaefer J.R., and Hofbauer L.C. Low serum levels of soluble RANKL are associated with the presence of coronary artery disease in men. Circulation 107 (2003) e76
68. Diez-Ruiz A., Tilz G.P., Zangerle R., et al. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 54 (1995) 1-8
69. Schoppet M., Al-Fakhri N., Franke F.E., et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 89 (2004) 4104-4112
70. Li J.H., Kirkiles-Smith N.C., McNiff J.M., and Pober J.S. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol 171 (2003) 1526-1533
71. Min J.K., Kim Y.M., Kim S.W., et al. TNF-related activation-induced cytokine enhances leukocyte adhesiveness: induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-kappaB activation in endothelial cells. J Immunol 175 (2005) 531-540
72. Secchiero P., Corallini F., di Iasio M.G., Gonelli A., Barbarotto E., and Zauli G. TRAIL counteracts the pro-adhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 105 (2005) 3413-3419
73. Alladina S.J., Song J.H., Davidge S.T., Hao C., and Easton A.S. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2. J Vasc Res 42 (2005) 337-347
74. Secchiero P., Zerbinati C., Rimondi E., et al. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61 (2004) 1965-1974
75. Michowitz Y., Goldstein E., Roth A., et al. The role of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol 45 (2005) 1018-1024
76. Secchiero P., Corallini F., Beltrami A.P., et al. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis (2009 Nov 10) [Epub ahead of print]
77. Zauli G., Pandolfi A., Gonelli A., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially up-regulates nitric oxide and postanoid production in primary human endothelial cells. Circ Res 92 (2003) 732-740
78. Sato K., Niessner A., Kopecky S.L., Frye R.L., Goronzy J.J., and Weyand C.M. TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med 203 (2006) 239-250
79. Janssen E.M., Droin N.M., Lemmens E.E., et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434 (2005) 88-93
80. Kaplan M.J., Ray D., Mo R.R., Yung R.L., and Richardson B.C. TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol 164 (2000) 2897-2904
81. Sorescu D., Weiss D., Lassegue B., et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105 (2002) 1429-1435
82. Cooke J.P. Does ADMA cause endothelial dysfunction?. Arterioscler Thromb Vasc Biol 20 (2000) 2032-2037
83. Xiang G.D., Sun H.L., and Zhao L.S. Changes of osteoprotegerin before and after insulin therapy in type I diabetic patients. Diabetes Res Clin Pract 76 (2007) 199-206
84. Shin J.Y., Shin Y.G., and Chung C.H. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 29 (2006) 1664-1666
85. Pritzker L.B., Scatena M., and Giachelli C.M. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell 15 (2004) 2834-2841
86. Avignon A., Sultan A., Piot C., Elaerts S., Cristol J.P., and Dupuy A.M. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 28 (2005) 2176-2180
87. Hetzel J., Balletshofer B., Rittig K., et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory bio-markers. Arterioscler Thromb Vasc Biol 25 (2005) 1804-1809
88. Pistrosch F., Passauer J., Fischer S., et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27 (2004) 484-490
89. United States Renal Data System. Causes of death. Am J Kidney Dis 32 (1998) S81-S88
90. Schawrz U., Buzello M., Ritz E., et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15 (2000) 218-223
91. Stenvinkel P., Pecoits-Filho R., and Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 14 (2003) 1927-1939
92. Luo G., Ducy P., McKee M.D., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386 (1997) 78-81
93. Jahnen-Dechent W., Schaefer C., Heiss A., et al. Systemic inhibition of spontaneous calcification by the serum protein alpha 2-HS glycoprotein/fetuin. Z Kardiol 90 Suppl 3 (2001) 47-56
94. Moe S.M., O'Neill K.D., Reselerova M., et al. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant 19 (2004) 2387-2393
95. Raggi P., Boulay A., Chasan-Taber S., et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?. J Am Coll Cardiol 39 (2002) 695-701
96. Kazama J., Shigematsu T., Yano K., et al. Increased circulating osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 39 (2002) 525-532
97. Gonnelli S., Montagnani A., Caffarelli C., et al. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis. J Endocrinol Invest 28 (2005) 534-539
98. Nitta K., Akiba T., Uchida K., et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 19 (2004) 1886-1889
99. Nishiura R., Fujimoto S., Sato Y., et al. Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients. Am J Nephrol 29 (2009) 257-263
100. Mesquita M., Demulder A., Damry N., et al. Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Clin Chem Lab Med 47 (2009) 339-346
101. Morena M., Dupuy A.M., Jaussent I., et al. A cut-off value of plasma osteoprotegerin value may predict the presence of coronary artery calcification in chronic kidney disease patients. Nephrol Dial Transplant 24 (2009) 3389-3397
102. Sato T., Tominaga Y., Iwasaki Y., et al. Osteoprotegerin levels before and after renal transplantation. Am J Kidney Dis 38 Suppl 1 (2001) S175-S177
103. Ho K.K., Anderson K.M., Kannel W.B., Grossman W., and Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88 (1993) 107-115
104. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91 (2002) 988-998
105. Meldrum D.R. Tumor necrosis factor in the heart. Am J Physiol 274 (1998) R577-R595
106. Yndestad A., Damås J.K., Geir Eiken H., et al. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res 54 (2002) 175-182
107. Roselló-Lletí E., Rivera M., Martínez-Dolz L., et al. Inflammatory activation and left ventricular mass in essential hypertension. Am J Hypertens 22 (2009) 444-450
108. Ueland T., Yndestad A., Øie E., et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 111 (2005) 2461-2468
109. Yan A.T., Yan R.T., Spinale F.G., et al. Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. Eur J Heart Fail 10 (2008) 125-128
110. Liu W., Feng W., Wang F., et al. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease. Exp Mol Pathol 84 (2008) 213-217
111. Ueland T., Jemtland R., Godang K., et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 44 (2004) 1970-1976
112. Omland T., Ueland T., Jansson A.M., et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 51 (2008) 627-633
113. Rasmussen L.M., Tarnow L., Hansen T.K., Parving H.H., and Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 154 (2006) 75-81
114. Abedin M., Omland T., Ueland T., et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 99 (2007) 513-518
115. Helske S., Kovanen P.T., Lindstedt K.A., et al. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail 9 (2007) 357-363
116. Omland T., Drazner M.H., Ueland T., et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 49 (2007) 1392-1398
117. Kiechl S., Schett G., Wenning G., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109 (2004) 2175-2180